Navigation Links
National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
Date:2/19/2009

INDIANAPOLIS, LOS ANGELES, SOUTH SAN FRANCISCO, Calif., WASHINGTON, Feb. 19 /PRNewswire/ -- Tens of thousands of people surviving a cancer diagnosis may benefit from a new program being introduced today by a collaboration of health care providers, patient advocates, health benefit insurers and a biotechnology company.

Journey Forward ( www.JourneyForward.org ), which is launching as a pilot program in California, Colorado, Maine, Nevada and New Hampshire, promotes physician and patient understanding of the post-treatment effects of cancer. By facilitating the development of a survivorship care plan, the program aims to improve continuity and coordination of care for cancer survivors throughout their lives.

This first-of-its-kind program was created in response to recommendations by the independent Institute of Medicine (IOM), which concluded in a November 2005 report that "the consequences of cancer and its treatment are substantial" and largely unmet. The report says many cancer survivors are "lost in transition" from active treatment to survivorship, with few clues about how to manage their follow-up care and about the physical and mental health problems that may result from their treatment.

"Patients often have no idea what to expect once they've finished their cancer treatment, and neither do the primary care providers on their team," said Dr. Patricia Ganz, director of the UCLA Cancer Survivorship Center and a nationally renowned expert on survivorship. "There is a need for better post-treatment coordination of care and the treatment summary and survivorship care plan is a place to start. Survivors often don't know what kind of surveillance and follow-up care they need to monitor for disease recurrence or any late effects that may result from their cancer treatment."

"By providing tools and information to both partie
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
2. National Health Care List Ranks McLaren Health Care Top in Michigan; 16th in Nation
3. Osteotech Receives 13485:2003 ISO Certification; Company Meets International Standards for Medical Device Manufacturing
4. National Committee For Quality Assurance (NCQA) Awards MVP Health Care Excellent Accreditation Status For Its HMO/POS Plan
5. IOF joins ECCEO9 at leading international meeting in Athens
6. Remuda Ranch Seeks to Increase Awareness of Eating Disorders Among Males During National Eating Disorders Awareness Week (NEDAW), February 22-28, 2009
7. National Dental Insurer United Concordia Successfully Launches Real-Time Claims Processing with Tesia-PCI
8. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
9. HUYA Bioscience International Announces Collaboration Agreement With the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
10. China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results
11. Quantros President Appears on National TV Promoting Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... by researchers from the Medical College of Wisconsin, in ... pain and other sickle cell disease complications in children. ... providers and patients were also identified. The study ... of pediatrics at the Medical College and Children,s Research ... presented at the American Society of Hematology meeting Dec. ...
(Date:12/6/2009)... ON. Dec. 6, 2009 A new study provides ... known as venous thromboembolism (VTE). , The condition ... every year, and occurs when an abnormal clot forms ... causing pain and swelling. In some cases, the clot ... through the heart to the lungs, causing a potentially ...
(Date:12/5/2009)... ORLEANSA new three-drug combination has shown in a phase ... effective regimen" in the treatment of patients newly diagnosed ... in bone marrow, say researchers from Dana-Farber Cancer Institute. ... of the 66 patients treated with the drug combination ... "very good partial response rate" in the phase 2 ...
(Date:12/5/2009)... Youngest Babies, This Type of Blood Cancer Is Most ... 5 Pediatric oncologists have identified specific genes, dubbed ... an often-fatal form of leukemia in infants. By more ... predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... Center helps companies develop and test their cleaning processes. The technology ... of industries and solve problems for customers relating to cleaning parts, ... ... 2009 -- Midbrook, Inc , a Jackson, MI-based company, is ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... the Scandinavian Prostate Cancer Group Study 4 (SPCG-4) reported ... watchful waiting after a median of 8.2 years of ... Sweden the results after 3 more years of follow-up ... , The SPCG-4 trial which predominantly included ...
... more than one year after it was created, the ... of Texas M. D. Anderson Cancer Center has ... aimed at inspiring generations of women scientists to come.Legends ... at M. D. Anderson Cancer Center presents the reflections ...
... 2009 Forest Laboratories, Inc. (NYSE: FRX ... Administration (FDA) has approved the Company,s supplemental New Drug ... and maintenance treatment of Major Depressive Disorder (MDD) in ... only the second antidepressant to be approved for the ...
... treatments for cognitive disorders, researchers say , , FRIDAY, ... functions on "the edge of chaos," at a ... U.K.-based researchers who said their finding could help ... , The researchers used medical imaging to ...
... MEDICAL CORP. (NYSE: CMN ) announced the ... President and Chief Executive Officer. Mr. Krakauer will also ... Cantel in September 2004, Mr. Krakauer served as Executive Vice ... Board concurrently appointed Seth R. Segel, Senior Vice President - ...
... Today, the Migraine Research Foundation (MRF) announced a new ... adolescent migraine called FOR OUR CHILDREN. The new ... the understanding of migraine and its causes and treatments ... , Migraine is very common in children ...
Other Medicine News:Health News:SPCG-4 trial: Update on watchful waiting versus radical prostatectomy 2Health News:New Book Chronicles the Journeys of Women Physicians and Scientists to the Front Lines of Fighting Cancer 2Health News:New Book Chronicles the Journeys of Women Physicians and Scientists to the Front Lines of Fighting Cancer 3Health News:New Book Chronicles the Journeys of Women Physicians and Scientists to the Front Lines of Fighting Cancer 4Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 2Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 3Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 4Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 5Health News:Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents 6Health News:Cantel Medical Corp. Names Andrew Krakauer as CEO and Announces Other Corporate Appointments 2Health News:New initiative to support pediatric migraine research is announced 2
(Date:12/4/2009)... Dec. 4 Chemistry World recently highlighted a ... and Manufacturers of America ( PhRMA ) that identifies ... related conditions. ,, The report found that the ... These drugs are either in human clinical trials or awaiting ...
(Date:12/4/2009)... SAN DIEGO, Calif., Dec. 4 Suneva Medical, a ... of Philip Ranker as Vice President and Chief Financial ... all Suneva Medical,s general and administrative functions including finance, ... will also serve on the Company,s senior management team. ...
(Date:12/4/2009)... TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced ... Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected ... across the country. The grand prize is an in-person meeting ... type 1 diabetes like Nick, are: Caleb, age 6, from ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Kendall Jackson Hosts Five Month Online Charity Auction Featuring Collectibles From Champion Thoroughbred 50774 1Kendall Jackson Hosts Five Month Online Charity Auction Featuring Collectibles From Champion Thoroughbred 50774 2Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 50773 1Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 50773 2Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 50773 3Dr John Mach Appointed Chief Medical Officer at XLHealth 50771 1Dr John Mach Appointed Chief Medical Officer at XLHealth 50771 2
... FRANCISCO, Calif., March 25 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology, today announced that it has reached its enrollment ... Picoplatin Efficacy After Relapse) trial. This global, pivotal Phase ... picoplatin in patients with recurrent small cell lung cancer ...
... 25 Amicus Therapeutics (Nasdaq: FOLD ) today ... Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods ... of isofagomine, the active ingredient in the Company,s investigational drug ... Gaucher disease. The patent will expire in 2027. ...
Other Medicine Technology:Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 2Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 3Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 4Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 2Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: